Please select the eligibility criteria that correspond to the clinical trial below.
Title: Maternal Docosa-Hexaenoic Acid (DHA) Supplementation and Offspring Neurodevelopment in India (DHANI-2)
Brief Summary: DHANI-2 is an extension to DHANI (NCT01580345) which proposes to extend maternal supplementation (DHA or Placebo) from \<20 weeks of gestational age through 6 months postpartum and infant follow-up through 12 months. Leveraging the Randomized Controlled Trial (RCT) design, DHANI-2 aims to assess the role of maternal DHA supplementation on infant neurodevelopment and body growth. It also intends to enhance the mechanistic understanding by the addition of repeated biochemical measures from mother-child dyads.


Options:
A: Inclusion Criteria:

* age 18 years or older
* Currently pregnant 12-22 weeks
* Singleton pregnancy
* Consuming fish \<=2 times per month

Exclusion Criteria:

* Inability to answer questionnaires in English
* Plans to leave study area prior to delivery
* Would never eat fish (e.g. vegan, allergy to fish)
B: Inclusion Criteria:

* Willing, healthy singleton gestation of ≤ 20 weeks (scan report must)
* 18-35 years
* Hb \> 7 g/dL
* Non-fasting glucose as per Diabetes in Pregnancy Study Group of India (DIPSI) criteria (\<140mg/dL)
* No history of chronic diseases (heart disease, diabetes, liver disorders, cancer, epilepsy, HIV, thyroid) or
* High risk pregnancy (short stature\*\*, molar pregnancy++, HBsAg positive, as advised by physicians)

  * \<143 cm ++ A molar pregnancy starts when an egg is fertilized, but instead of a normal, viable pregnancy resulting, the placenta develops into an abnormal mass of cysts.

Exclusion Criteria:

* Women allergic (if aware) to any of the test products.
* Women at high risk for hemorrhagic bleeding, clotting (if aware).
* Women with high-risk pregnancies (history and prevalence of pregnancy complications, including abruptio placentae, preeclampsia, pregnancy-induced hypertension, any serious bleeding episode in the current pregnancy, and/ or physician referral); and/or diagnosed chronic degenerative disease(s) such as diagnosed heart disease, cancer, stroke or diabetes (as omega-3 could raise blood sugar and lower insulin production).
* Women consuming omega-3 supplements or having used these in 3 months preceding the intervention period.
* Reported participation in another biomedical trial 3 months before the start of the study or during the study (not to get the results of the present study contaminated).
C: Inclusion Criteria:

* Women who were diagnosed as gestational diabetes mellitus (GDM) between 24 and 28th week of pregnancy
* Women with GDM and accepted to be participate in the study
* Women younger that 40 years old
* The newborns of the women with GDM

Exclusion Criteria:

* The history of Type 1 diabetes melitus
* Abnormal glucose tolerance \<20th gestational week
* The history of chronic illness in the mother
* Women who eat fish \<2 times in a week
* Any history of sea-food allergy in the mother
D: Inclusion Criteria:

* Gestational age \<= 15th week of gestation
* Age: 18-43 years
* Written informed consent
* Body mass index (BMI) before pregnancy between 18 and 30 km/m2

Exclusion Criteria:

* High risk pregnancy
* Hypertonus
* Chronic diseases (i.e. diabetes mellitus)
* Psychiatric diseases
* Former supplementation with LC-PUFA

Answer: B